Mahzi Therapeutics

CLOSING SOON: Developing precision therapies for genetic disorders affecting children

https://wefunder.com/mahzi.therapeutics

Total raised on Wefunder: 352522

Total investors: 147

Quick facts

  • $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
  • Completing patient enrollment in first-ever gene therapy clinical trial for Pitt-Hopkins syndrome
  • CEO with 20+ years of experience at Merck and rare disease pioneers Genzyme & Ultragenyx
  • Leadership team from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute
  • Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups
  • $60M raised from leading VCs Venrock, HealthCap, Droia Ventures & HBM Partners
  • ️​ Forbes 2026 Feature: “This Biotech Lets Families Invest in its Gene Therapy”
  • Targeting a $16B market with 800+ rare neurogenetic addressable disorders

Team profiles

Featured investor profiles

Invest in Mahzi Therapeutics

CLOSING SOON: Developing precision therapies for genetic disorders affecting children

FIRST GOAL HIT (You can still invest)

$34,537,221

raised from 156+ investors
INVESTMENT TERMS
Preferred Stock
$87.9M pre-money valuation $3.47 per share
Posts